Scholarlink

<p>The relationship between plasma or cerebrospinal fluid (CSF) amino acid levels and the pathophysiology of Parkinson’s disease (PD) remains unclear. We aimed to examine the association of plasma and CSF amino acid levels with the nigrostriatal dopaminergic neurons and the clinical symptoms of newly diagnosed drug-naïve patients with PD. This was a cross-sectional study using the Jikei University PD registry. A total of 45 amino acids were measured in both plasma and CSF, and their associations with key clinical parameters were investigated. Multiple linear regression analyses were conducted to evaluate whether amino acids served as major explanatory variables for clinical parameters in PD. Forty-five drug-naïve patients were enrolled. The mean age was 68.6 ± 9.6, and disease duration was 2.5&#xa0;years (± 2.1). MDS-UPDRS Part III score averaged 28.1 (± 13.3). Among the measured plasma and CSF amino acids, only CSF taurine levels were identified as independent factors for SBR, MDS-UPDRS Part II, and Part III scores in multivariate analysis (β = 0.39 [95% CI 0.13 to 0.65, p = 0.005], –0.46 [95% CI –0.76 to –0.15, p = 0.004], –0.39 [95% CI –0.73 to –0.05, p = 0.02], respectively). Higher CSF taurine levels were associated with more preserved SBR on <sup>123</sup>I-FP-CIT SPECT and better activities of daily living and motor symptoms, suggesting that CSF taurine may be involved in the mechanism of nigrostriatal dopaminergic degeneration and exert a neuroprotective effect on dopaminergic neurons.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Reduced cerebrospinal fluid taurine is associated with nigrostriatal dopaminergic deficits in drug-naïve Parkinson’s disease

  • 期刊论文

  • 发表日期：

    2025年9月29日

查看全文
  • Masahiro Mimori,
  • Tadashi Umehara,
  • Hiroki Takatsu,
  • Motohiro Okumura,
  • Marina Masui,
  • Hiroyuki Kida,
  • Masakazu Ozawa,
  • Haruhiko Motegi,
  • Asako Onda,
  • Hiromasa Matsuno,
  • Teppei Komatsu,
  • Kenichi Sakuta,
  • Kenichiro Sakai,
  • Shusaku Omoto,
  • Hidetaka Mitsumura,
  • Hidetomo Murakami,
  • Yasuyuki Iguchi

摘要

The relationship between plasma or cerebrospinal fluid (CSF) amino acid levels and the pathophysiology of Parkinson’s disease (PD) remains unclear. We aimed to examine the association of plasma and CSF amino acid levels with the nigrostriatal dopaminergic neurons and the clinical symptoms of newly diagnosed drug-naïve patients with PD. This was a cross-sectional study using the Jikei University PD registry. A total of 45 amino acids were measured in both plasma and CSF, and their associations with key clinical parameters were investigated. Multiple linear regression analyses were conducted to evaluate whether amino acids served as major explanatory variables for clinical parameters in PD. Forty-five drug-naïve patients were enrolled. The mean age was 68.6 ± 9.6, and disease duration was 2.5 years (± 2.1). MDS-UPDRS Part III score averaged 28.1 (± 13.3). Among the measured plasma and CSF amino acids, only CSF taurine levels were identified as independent factors for SBR, MDS-UPDRS Part II, and Part III scores in multivariate analysis (β = 0.39 [95% CI 0.13 to 0.65, p = 0.005], –0.46 [95% CI –0.76 to –0.15, p = 0.004], –0.39 [95% CI –0.73 to –0.05, p = 0.02], respectively). Higher CSF taurine levels were associated with more preserved SBR on 123I-FP-CIT SPECT and better activities of daily living and motor symptoms, suggesting that CSF taurine may be involved in the mechanism of nigrostriatal dopaminergic degeneration and exert a neuroprotective effect on dopaminergic neurons.